Improvement in Glycemic Response After Bariatric Surgery
ConditionBariatric Surgery
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorWeizmann Institute of Science
About this trial
decipher the role of microbiota in glycemic response change after bariatric surgery
Eligibility criteria
This trial accepts healthy volunteersQualifiers
candidates of bariatric surgery or cholecystectomy
age 18-70
male/female
Disqualifiers
previous bariatric surgery
type 1 diabetes
antibiotic treatment 3 months prior to the study
probiotic treatment 3 months prior to the study
Trial population
patients arriving at the outpatient unit at Tel Aviv Sourasky medical center
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
sleeve gastrectomy surgery
Procedure/Surgeryparticipants undergoing sleeve gastrectomy surgery
gastric bypass surgery
Procedure/Surgeryparticipants undergoing gastric bypass surgery
control
Procedure/Surgerycholecystectomy
Pancreatectomy
Procedure/SurgeryCollecting a sample of an unidentified healthy pancreas to extract insulin-secreting beta cells from the sample
Treatment groups
120 Participants
are divided into 4 treatment groupsGroup A: sleeve gastrectomy surgery1 intervention
Group B: gastric bypass surgery1 intervention
Group C: cholecystectomy1 intervention
Group D: Pancreatectomy1 intervention
Trial outcomes
Primary outcomes
1
Glycemic response
The glycemic response will be measured by taking a blood test (glucose) after 12 hours fast and a second blood test (glucose) after an OGTT(oral glucose tolerance test) of 50 g glucose
Time frame
up to 4 years2
microbiota composition
The microbiota composition will be assessed using the stool samples of the participants.
Time frame
up to 4 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Weizmann Institute of Science
Lead sponsor
Tel-Aviv Sourasky Medical Center
Collaborator
Source ClinicalTrials.gov